Recent Progress in Chitosan-Based Nanomedicine for Its Ocular Application in Glaucoma

Area of Science:

• Ophthalmology
• Nanomedicine
• Drug Delivery Systems

Background:

• Glaucoma is a chronic eye disease causing irreversible vision loss, primarily due to high intraocular pressure.
• Conventional ocular drug delivery methods (eye drops, ointments) suffer from low bioavailability due to precorneal and corneal barriers.
• Poor drug residence time and corneal permeability limit the efficacy of current glaucoma therapies.

Purpose of the Study:

• To review recent research on chitosan-based nanoparticulate systems for glaucoma treatment.
• To highlight the advantages of chitosan nanoparticles in overcoming conventional drug delivery limitations.
• To analyze the impact of chitosan nanomedicine on ocular drug delivery and therapeutic performance.

Main Methods:

• Review of contemporary scientific literature on chitosan-based nanoparticulate systems for ocular drug delivery.
• Analysis of different chitosan nanoparticle formulations: chitosan core, chitosan-coated, and hybrid nanoparticles.
• Evaluation of studies focusing on mucoadhesion, corneal permeability, and bioavailability enhancement.

Main Results:

• Chitosan-based nanoparticulate systems demonstrate significant potential for improving ocular drug delivery in glaucoma.
• Mucoadhesive properties of chitosan enhance drug residence time on the ocular surface.
• These systems show promise in increasing corneal permeability and ocular bioavailability of antiglaucoma agents.

Conclusions:

• Chitosan-based nanomedicine offers a promising strategy to enhance the therapeutic efficacy of glaucoma treatments.
• Nanoparticulate systems, particularly those utilizing chitosan, can overcome the challenges associated with conventional ocular drug delivery.
• Further research into chitosan nanoparticles can lead to improved treatment outcomes for patients with glaucoma.